Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | MAP3K14 | Q99558 | 5/20 | 0.43 |
| ▸ | LCK | P06239 | 4/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7014522 | 0.91 | FGFR1 (0.54) | FGFR1MAP3K14LCKMKNK2MKNK1 | |
| SCHEMBL7020153 | 0.84 | MAP3K14 (0.38) | FGFR1MAP3K14LCKMKNK2MKNK1 | |
| SCHEMBL7027073 | 0.81 | FGFR1 (0.54) | FGFR1LCKMKNK2MKNK1 | |
| SCHEMBL7020638 | 0.81 | MKNK2 (0.52) | LCKMKNK2MKNK1JAK3 | |
| SCHEMBL7024457 | 0.80 | LCK (0.55) | MAP3K14LCKROCK1 | |
| SCHEMBL7024738 | 0.77 | ROCK1 (0.62) | LCKMKNK2MKNK1ROCK1 | |
| SCHEMBL7494174 | 0.75 | ROCK1 (0.44) | FGFR1MAP3K14LCKMKNK2MKNK1 | |
| SCHEMBL7552289 | 0.75 | NPC1 (0.56) | LCKMKNK2MKNK1 | |
| SCHEMBL7019537 | 0.75 | FGFR1 (0.41) | FGFR1LCKMKNK2MKNK1 | |
| SCHEMBL7021439 | 0.75 | JAK2 (0.53) | MAP3K14MKNK2MKNK1ROCK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |